explore -WSS

explore

author：Wikipedia 2025-09-29 20:53:08 - browse：51829

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Google's generative AI to analyze medical images — and talk to docs

entertainment

knowledge

Wikipedia

WSS

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

ActiGraph execs on goal of drug approvals with digital endpoints

St. Louis police protesters begin picking up checks in $4.9 million settlement

How CRISPR works, explained in two minutes

Baltimore teen accused of firing into crowd during block party mass shooting

Majority of Americans think Trump's Ga. election interference case is serious: POLL

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Alkermes shareholders re

Beware the threat of staffing cuts at the CDC

Hollywood unions extend contract negotiations for actors

Pennsylvania man bitten on the head by bear during attack in his garage

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Many breast cancer patients receive more radiation than needed

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Google's generative AI to analyze medical images — and talk to docs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Doctors are clamoring for more clarity on Paxlovid prescribing

leisure time

St. Louis police protesters begin picking up checks in $4.9 million settlement

Flash flood warnings continue for parts of Missouri, Illinois

Clinical trials must include more disabled people

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

New definition of a human embryo proposed amid rapid advances

Hilary may become 1st tropical storm to make landfall in California in 84 years

entertainment

knowledge

Wikipedia

Wikipedia